LOS ANGELES, Jan. 6, 2015 (GLOBE NEWSWIRE) -- Lion Biotechnologies, Inc. (LBIO) announced that president and CEO Elma Hawkins, PhD, will present at the Biotech Showcase on Monday, January 12, 2015. The conference is being held at the Parc 55 Wyndham Union Square Hotel in San Francisco. Dr. Hawkins will present at 3 p.m. PST in the Powell room on the third floor.
Now in its seventh year, Biotech Showcase is an investor and partnering conference that offers private and public biotechnology and life sciences companies with an opportunity to present to, and meet with, investors and pharmaceutical executives. This rapidly growing conference features multiple tracks of presenting companies, plenary sessions, workshops, networking, and an opportunity to schedule one-to-one meetings.
About Lion Biotechnologies
Lion Biotechnologies, Inc. is engaged in the development of T-cells and engineered T-cells for the treatment of various cancers. The company's lead product candidate, LN-144, is a ready-to-infuse, autologous T-cell therapy utilizing tumor-infiltrating lymphocytes (TIL) for the treatment of patients with metastatic melanoma, and is based on a clinical Cooperative Research and Development Agreement with the National Cancer Institute. TIL therapy is also being evaluated in physician-sponsored clinical trials at MD Anderson Cancer Center and the H. Lee Moffitt Cancer Center & Research Institute. For more information, please visit http://www.lionbio.com.
Forward Looking Statements
This press release contains certain forward-looking statements that are subject to a number of risks and uncertainties, including the risks relating to the Company's ability to conduct its Phase 2 clinical trial in metastatic melanoma and to further successfully develop or commercialize the Company's TIL technologies. Additional risks and uncertainties are described in the Company's most recently filed quarterly report on Form 10-Q and annual report on Form 10-K. Except as permitted by law, the Company undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.
CONTACT: Investor Relations The Trout Group Gitanjali Jain Ogawa 646-378-2949 email@example.comSource:Lion Biotechnologies, Inc.